TABLE 2.
Characteristics of patients with advanced metastatic triple‐negative breast cancer, grouped according to completion of 6 weeks of 19‐peptide vaccine monotherapy
| All (n = 14) | Completed (n = 10) | Did not complete (n = 4) | P value | |
|---|---|---|---|---|
| Age | ||||
| Median (range) | 55 (35‐82) | 55 (40‐82) | 52 (35‐80) | .91 a |
| HLA type | ||||
| A24 | 6 | 3 | 3 | NA |
| A2 | 8 | 7 | 1 | |
| A3 supertype | 5 | 4 | 1 | |
| A26 | 5 | 3 | 2 | |
| Performance status | ||||
| 0 | 7 | 6 | 1 | .56 b |
| 1 | 7 | 4 | 3 | |
| Systemic chemotherapy regimens c | ||||
| 1 | 3 | 3 | 0 | .11 b |
| 2 | 4 | 3 | 1 | |
| 3 | 3 | 3 | 0 | |
| 4 or more | 4 | 1 | 3 | |
| Lymphocytes (%) | ||||
| Median (range) | 29.9 (15.5‐48.4) | 34.1 (17.0‐48.4) | 24.3 (15.5‐44.3) | .41 a |
| Neutrophils (%) | ||||
| Median (range) | 57.3 (37.9‐74.0) | 55.1 (44.0‐74.0) | 67 (32.9‐71.0) | .69 a |
| CRP | ||||
| Median (range) | 0.3 (0.01‐11.7) | 0.2 (0.01‐11.7) | 0.6 (0.06‐1.45) | .47 a |
| OS from first vaccination (mo) | ||||
| Median (95% CI) | 11.5 (1.5‐42.0) | 24.0 (2.3‐not reached) | 1.4 (1.0‐6.0) | <.01 c , d |
| OS from first diagnosis (mo) | ||||
| Median (95% CI) | 80.0 (25.1‐179.7) | 80.0 (20.5‐164.6) | 106.6 (13.0‐193.8) | .52 d |
Abbreviations: CI, confidence interval; CRP, C‐reactive protein; HLA, human leukocyte antigen; NA, not available; OS, overall survival.
a
Student’s t test.
b
Fisher’s exact test.
c
Regimen numbers for postrecurrence cases (n = 10) or inoperable advanced cases (n = 4).
d
Log‐rank test.